Why the study?
Does high residual platelet reactivity after clopidogrel loading increase the risk of cardiac mortality and stent thrombosis in patients undergoing DES implantation for unprotected left main disease?
Does high residual platelet reactivity after clopidogrel loading increase the risk of cardiac mortality and stent thrombosis in patients undergoing DES implantation for unprotected left main disease?
High residual platelet reactivity after a 600-mg clopidogrel loading dose strongly predicts long-term cardiac death and stent thrombosis in patients undergoing DES implantation for unprotected left main disease.
Answers are grounded in this paper and cite their sources.
May identify high-risk left main DES patients; hypothesis-generating for reactivity-guided therapy and should not yet change practice.
BACKGROUND: No data exist about the impact of high residual platelet reactivity (HRPR) after clopidogrel loading on long-term clinical outcome in patients undergoing drug-eluting stent (DES) implantation for unprotected left main disease (ULMD). METHODS AND RESULTS: Consecutive patients who underwent percutaneous coronary intervention for ULMD had prospective platelet reactivity assessment by light transmittance aggregometry after a loading dose of 600 mg of clopidogrel. The primary end point of the study was cardiac mortality, and the secondary end point was stent thrombosis. From January 2005 to September 2008, 215 consecutive patients were treated with DES for ULMD. The incidence of HRPR after clopidogrel loading was 18.6%. The median follow-up was 19.3 months. The overall estimated 1-, 2- and 3-year cardiac mortality rate was 3.9+/-1.3%, 7.5+/-2.2%, and 12.2+/-3.4%, respectively. The 3-year cardiac mortality rate was 8.0+/-3.1% in the low residual platelet reactivity (LRPR) group and 28.3+/-10.4% in the HRPR group (P=0.005). The 3-year stent thrombosis rate was 4.2+/-1.8% in the low residual platelet reactivity group and 16.0+/-7.3% in the HRPR group (P=0.021). By forward stepwise regression analysis, HRPR after clopidogrel loading was the only independent predictor of cardiac death (hazard ratio, 3.82; 95% confidence interval,1.38 to 10.54; P=0.010) and stent thrombosis (hazard ratio, 3.69; 95% confidence interval, 1.12 to 12.09; P=0.031). CONCLUSIONS: HRPR after 600-mg clopidogrel loading is a strong marker of increased risk of cardiac death and DES thrombosis in patients receiving DES stenting for ULMD. Routine assessment of in vitro residual platelet reactivity after clopidogrel loading in patients with ULMD potentially suitable for DES-supported percutaneous coronary intervention should be considered to guide patient care decisions.
No takes yet. Share an insight, caveat, or question.
Migliorini et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: